Alembic Pharmaceuticals announced that its wholly owned US subsidiary, Alembic Pharmaceuticals Inc., has signed a definitive agreement to acquire Utility Therapeutics for approximately $12 million. The strategic acquisition strengthens Alembic Pharma position in the US pharmaceutical market, particularly in the treatment of urinary tract infections (UTIs).
Focus on UTI Treatment Pipeline
Utility Therapeutics specializes in the development of novel treatments for UTIs. It currently owns two key pharmaceutical products:
- Pivya, an FDA-approved medication for uncomplicated UTIs already available in the US.
- MEC, a pipeline product under development aimed at treating complicated UTIs.
Despite having minimal turnover in the last three years, Utility’s products represent valuable assets in a high-demand therapeutic area. Alembic intends to leverage these products to expand its US footprint and enhance its branded product portfolio.
Deal Structure and Financial Terms
According to the company, the acquisition cost comprises an upfront cash component and a profit-sharing arrangement based on future product revenues. The total payout will be disbursed in a staggered manner, contingent upon the achievement of certain developmental and commercial milestones.
As per Business Standard, industry experts believe the move could provide Alembic with a competitive edge in a growing therapeutic segment, particularly as antibiotic resistance continues to fuel demand for newer, effective treatments.
Strategic Growth Despite Recent Profit Decline
Alembic Pharma remains a vertically integrated research and manufacturing company with a strong global presence in generic drug markets. Its facilities hold approvals from major regulatory bodies, including the USFDA.
However, in its recent earnings report, Alembic posted a 12% decline in consolidated net profit, down to ₹156.89 crore in Q4 FY25, despite a 16.7% increase in net sales, which rose to ₹1,769.64 crore compared to Q4 FY24. The acquisition of Utility Therapeutics signals Alembic’s intent to diversify its revenue streams and strengthen long-term profitability.
